A multicenter, randomized phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT) for prostate cancer with relapse after initial hormonal therapy.
M. Takahashi
No relevant relationships to disclose
R. Kawabata
Employment or Leadership Position - Taiho Pharmaceutical
A. Kawano
No relevant relationships to disclose
Y. Murakami
No relevant relationships to disclose
Y. Sutou
No relevant relationships to disclose
T. Inai
No relevant relationships to disclose
S. Akazawa
No relevant relationships to disclose
T. Hamao
No relevant relationships to disclose
H. Hayashi
No relevant relationships to disclose
T. Fukawa
No relevant relationships to disclose
M. Takemura
No relevant relationships to disclose
Y. Yamamoto
No relevant relationships to disclose
K. Yamaguchi
No relevant relationships to disclose
H. Nakatsuji
No relevant relationships to disclose
T. Kishimoto
No relevant relationships to disclose
H. Izaki
No relevant relationships to disclose
T. Fukumori
No relevant relationships to disclose
H. Kanayama
No relevant relationships to disclose